StemCell Therapy

publication date: Oct. 18, 2019

The UCLA Jonsson Comprehensine Cancer Center has launched a CAR T-cell immunotherapy trialthat will attack cancer cells by simultaneously recognizing two targetsCD19 and CD20that are expressed on B-cell lymphoma and leukemia.

By launching a bilateral attack instead of using the conventional single-target approach, researchers are hoping to minimize resistance and increase the life expectancy for people diagnosed with these cancers.

One of the reasons CAR T cell therapy can stop working in patients is because the cancer cells escape from therapy by losing the antigen CD19, which is what the CAR T cells are engineered to target, Sarah Larson, a health sciences clinical instructor in hematology/oncology at UCLA Health and the principal investigator on the trial, said in a statement One way to keep the CAR T cells working is to have more than one antigen to target. So, by using both CD19 and CD20, the thought is that it will be more effective and prevent the loss of the antigen, which is known as antigen escape, one of the common mechanisms of resistance.

Up to two-thirds of the patients who experience relapse after being treated with the FDA-approved CD19 CAR T-cell therapy develop tumors that have lost CD19 expression. UCLA researchers are identifying and testing new strategies like this one so many more patients can benefit from the therapy.

In preclinical studiesled byYvonne Chen, an associate professor of microbiology, immunology, and molecular genetics at UCLA and the sponsor of the trial, the team was able to show that by simultaneously attacking two targets, the engineered T cells developed in her lab could achieve a much more robust defense compared to conventional, single-target CAR T cells against tumors in mice.

Chens team designed the CARs based on the molecular understanding of the CARs architecture, the antigen structure and the CAR/antigen binding interaction to achieve optimal T cell function. This design helps the T cells have dual-antigen recognition to help prevent antigen escape.

Based on these results, were quite optimistic that the bispecific CAR can achieve therapeutic improvement over the single-input CD19 CAR thats currently available, said Chen, who is also the co-director of the Jonsson Cancer Centers Tumor Immunology Program and a member of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.

This first-in-humans study will evaluate the therapy in patients with non-Hodgkins B-cell lymphoma or chronic lymphocytic leukemia that has come back or has not responded to treatment. The goal is to determine a safe therapeutic dose.

Patients enrolled in the trial will have their white blood cells (T cells) collected intravenously then reengineered in the laboratory so the T cells can produce tumor-specific receptors (CARs), which allow the T cells to recognize and attack the CD19 and CD20 proteins on the surface of tumor cells. The new smarter and stronger T cells are then infused back into the patient and primed to recognize and kill cancer cells.

The trial is currently only offered at UCLA.

Results from STELLAR trial in MPM published in The Lancet Oncology

Novocure said the results from the STELLAR trial were published inThe Lancet Oncology.

The STELLAR trial was a prospective, single-arm trial including 80 patients that studied the use of Tumor Treating Fields, delivered via the NovoTTF-100L System, in combination with pemetrexed plus cisplatin/carboplatin as a first-line treatment for patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma.

Data showed a median overall survival of 18.2 months (95 percent CI, 12.1 months-25.8 months) for patients treated with NovoTTF-100L and pemetrexed plus cisplatin or carboplatin. One- and two-year survival rates were 62.2 percent (95 percent CI, 50.3 percent-72.0 percent) and 41.9 percent (95 percent CI, 28.0 percent-55.2 percent), respectively. No serious systemic adverse events were considered to be related to the use of NovoTTF-100L. The most common mild to moderate adverse event was skin irritation beneath the transducer arrays.

The STELLAR trial demonstrated encouraging overall survival results with no increase in systemic toxicity observed in MPM patients treated with Tumor Treating Fields and standard chemotherapy, Giovanni Luca Ceresoli, head of pulmonary oncology at the Humanitas Gavazzeni Hospital in Bergamo, Italy, and principal investigator in the STELLAR trial, said in a statement. The median overall survival of 18.2 months is impressive given that MPM is a tumor with a dismal prognosis and few effective therapeutic options.

Median progression free survival was 7.6 months (95 percent CI, 6.7 percent-8.6 percent) for patients treated with NovoTTF-100L and pemetrexed plus cisplatin or carboplatin. There was a 97 percent disease control rate in patients with at least one follow-up CT scan performed (n=72). 40 percent of patients had a partial response, 57 percent had stable disease and 3 percent had progressive disease.

IASLC invites comments on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapy

The International Association for the Study of Lung Cancer announced an open comment period for the IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapy paper.

The paper has been made available hereto provide an opportunity for public review of new draft recommendations. The open comment period runs from Oct. 14 to Nov. 7.

With the recent growing number of neoadjuvant therapy clinical trials for non-small cell lung cancer, there is a great need for standardization of specimen processing since major pathologic response has consistently been shown to be an important prognostic indicator.

The purpose of the paper is to outline detailed recommendations on how to process lung cancer resection specimens and to define pathologic complete response including major pathologic response and pathologic complete response following neoadjuvant therapy.

Currently there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice, Giorgio Scagliotti, past president of the IASLC and co-author of the paper, said in a statement. There is also a lack of precise definitions on the degree of pathologic response, including MPR or pCR.

IASLC is making an effort to collect such data from existing and future clinical trials. These recommendations are intended as guidance for clinical trials, although it is hoped they can be viewed as suggestions for good clinical practice outside of clinical trials, to improve consistency of pathologic assessment of treatment response.

The recommendations were developed by the IASLC Pathology Committee in collaboration with an international multidisciplinary group of experts in medical oncology, thoracic surgery and radiology.

We are crossing an exciting period of preclinical and clinical research around thoracic oncology. Targeted therapies and immunotherapy have greatly improved survival expectations in advanced disease and we believe they can equally generate benefit in the systemic therapy of earlier stages of the disease, Scagliotti said in a statement. Our initiative aims to use rigorous experimental conditions to analyze tissue specimens, collected in the context of already performed or ongoing neoadjuvant studies with targeted therapies and immunotherapy, to generate a diagnostic algorithm to be used in all subsequent studies in order to accelerate the scientific information about the clinical benefit produced by the neoadjuvant approach.

Expert second opinion improves reliability of melanoma diagnoses

Getting a reliable diagnosis of melanoma can be a significant challenge for pathologists.The diagnosis relies on a pathologists visual assessment of biopsy material on microscopic slides, which can often be subjective.

Of all pathology fields, analyzing biopsies for skin lesions and cancers has one of the highest rates of diagnostic errors, which can affect millions of people each year.

Now, a study led by UCLA researchers, has found that obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology can help improve the accuracy and reliability of diagnosing melanoma, one of the deadliest and most aggressive forms of skin cancer.

A diagnosis is the building block on which all other medical treatment is based,Joann Elmore, a professor of medicine at the David Geffen School of Medicine at UCLA and researcher at the UCLA Jonsson Comprehensive Cancer Center, said in a statement.All patients deserve an accurate diagnosis. Unfortunately the evaluation and diagnosis of skin biopsy specimens is challenging with a lot of variability among physicians.

In the study, led by Elmore and colleagues, the value of a second opinion by general pathologists and dermatopathologists were evaluated to see if it helped improve thecorrect diagnostic classification.

To evaluate the impact of obtaining second opinions, the team used samples from the Melanoma Pathology Study, which comprises of 240 skin biopsy lesion samples. Among the 187 pathologists who examined the cases, 113 were general pathologists and 74 were dermatopathologists.

The team studied misclassification rates, which is how often the diagnoses of practicing US pathologists disagreed with a consensus reference diagnosis of three pathologists who had extensive experience in evaluating melanocytic lesions. The team found that the misclassification of these lesions yielded the lowest rates when first, second and third reviewers were sub-specialty trained dermatopathologists. Misclassification was the highest when reviewers were all general pathologists who lacked the subspecialty training.

Our results show having a second opinion by an expert with subspecialty training provides value in improving theaccuracy of thediagnosis, which is imperative to helpguide patients to the most effective treatments, said Elmore, whois also the director of the UCLA National Clinician Scholars Program.

Elmore is now studying the potential impact of computer machine learning as a tool to improve diagnostic accuracy. She is partnering with computer scientists who specialize in computer visualization of complex image information, as well as leading pathologists around the globe to develop an artificial intelligence (AI)-based diagnostic system.

Michael Piepkorn of the University of Washington School of Medicine is the studys first author. Raymond Barnhill of the Institut Curie is the co-senior author.

The study was published in JAMA Network Open and supported by NCI.

Go here to read the rest:
UCLA opens CAR T-cell trial focused on the most common types of lymphoma, leukemia - The Cancer Letter Publications

Regenerative Medicine research is poised to change the way we know health care. This cutting-edge technology demands new tools and solutions that are able to keep up with the development in personalised medicine. Texture Analysis, which has long been used by the pharmaceutical, food and cosmetic industries, is increasingly being used to evaluate properties of medical devices.

Texture Analysis refers to calculating properties such as firmness, adhesiveness, compressive strength, swelling/absorption, in addition to relaxation behaviour, fatigue and brittleness. Regulatory agencies, including the FDA, have used the TA.XTplus Texture Analyser to evaluate medical devices. In addition, the patent literature increasingly relies on texture analysis to validate claims.

In its most basic configuration, the instrument carries loadcells ranging from 500 g to 750 kg which provide the force measurement for compression or tensile testing of samples. The arm of the instrument moves up or down at speeds from 0.01-40 mm/s collecting data at very precise resolution at up to 2000 points per second.

The mechanical function of medical devices and engineered tissues is a primary endpoint for the successful regeneration of many biological tissues. It is critical that the mechanical function be characterised and compared to initial benchmark function to determine quality control standards for the next generation of health care.

The metered-dose inhaler (MDI) delivers a precise, reproducible dose of drug accurately to the deep lung. It is also well accepted by patients who depend on MDIs in their treatment and therefore it is essential to constantly improve this technology. Patients need to rely on their inhaler to provide them with the required medication which is often at a crucial time when physical strength may be very low.

The metering valve, whose performance is assessed with this test, is a critical component of a finished metered-dose inhaler. The interaction between the elastomeric components and the formulation can significantly affect product performance. A change in formulation, for example implementing a new propellant system, may necessitate a complete redesign of the valve system in order to successfully deliver the drug with the minimum of difficulty.

The Inhaler Support Rig provides a holding device for the inhaler so that it can be tested with a hemispherical probe which best mimics the action of the finger for drug delivery. The force required to push down on the inhaler to deliver the drug is measured. This assesses the performance of the metering valve.

Metered Dose Inhaler test and typical comparative graphs

An assessment of syringeability is required to assess the potential effects of formulations and their subsequent mechanical consequences to reach an optimal performance. The syringeability of each formulation is determined using a Universal Syringe Rig on a Texture Analyser. This innovative attachment effectively measures the aspiration and extraction forces of syringe pistons. The extraction force quantifies how easily the injectable material is expressed during syringe depression and material discharge. This measured force impacts patient comfort during injection and affects how the material is received when deposited under the skin. This rig also allows manufacturers to determine the force required to withdraw the plunger from the syringe. The method enables syringe manufacturers and pharmaceutical companies to precisely quantify the performance of their products so that they are able to optimise usability and patient comfort, while guaranteeing quality control and product safety. The universal design allows a wide range of syringe types and sizes (from 5-50mm diameter) to be supported securely for testing.

Formulations are transferred into identical plastic syringes to a constant height. The content of each syringe is fully expressed using the Texture Analyser in compression mode and the resistance to expression is determined from the area under the resultant force-time plot. Increased work of syringeability is denoted by increased areas under the curves.

Universal Syringe Test Rig and assessment of force to expel syringe contents

Needle sharpness, which is an important characteristic for patient comfort, may be determined by a puncture test where the needle is held by a Tensile Grip on the Texture Analyser and is pushed through a standard substrate. The force required for insertion and extraction is measured.

Hypodermic Needle Testing and typical comparative graphs

Due to the challenging service environment that stents face in vivo, the radial stiffness of a stent is critical to its function of keeping the arteries open and eliminating abrupt closure or restenosis. Restenosis has been correlated with geometric properties of stents, such as the number of struts, the strut width and thickness, and the geometry of the cross section of each strut. A large number of stents with different geometric and mechanical features are available on the market. The therapeutic efficacy of stents depends largely on their mechanical properties, thereby influencing the choice of stents for treating specific tissues.

By performing texture analysis tests on the stents, researchers can improve design and performance. A compression test using a cylinder probe is the most common test to measure structural integrity.

The stent is positioned centrally under a cylinder probe and compressed to a chosen distance. During the test the force is shown to increase gradually as compression continues. The distances at 3 force values are recorded as measures of increasing stiffness.

Stent compression test and typical comparative graphs

For a full summary of typical texture analysis tests that can be performed on medical device products:

This information has been sourced, reviewed and adapted from materials provided by Stable Micro Systems Ltd.

For more information on this source, please visit Stable Micro Systems Ltd.

Read more here:
How to Measure the Physical Properties of Medical Devices - AZoM

HYDERABAD, India, Oct. 15, 2019 /PRNewswire/ -- LifeNet Health's Dermacell AWM, the world's most-advanced acellular dermal matrix (ADM) for wound treatment, is the first human ADM available in India. This introduction provides access to proven therapy for millions of patients in India suffering from chronic wounds.

Each year, as many as 100,000 patients in India face amputation due to a chronic wound. With more than 65 million people with diabetes and 7.5 million new cases diagnosed each year, the incidence of severe wounds and amputation is steadily increasing in India. Dermacell AWM has been shown to effectively treat challenging wounds, thereby reducing the threat of amputation and its debilitating impacts such as decreased quality of life and increased mortality.

"We are proud to offer Dermacell AWM as the first therapy of its kind in India," said Rony Thomas, President and CEO of LifeNet Health, a global leader in regenerative medicine. "It's a truly unique clinical solution to help patients overcome severe wounds and avoid the devastating effects of amputation."

Dermacell AWM has been utilized as an effective treatment in the U.S., the European Union and Latin America prior to its availability in India. It is supported by multiple studies that show it can bring serious wounds to complete resolution with fewer applications than conventional care or other graft materials. In a May 2019 clinical review, wounds treated with Dermacell AWM healed with an average of just one application, compared to an average of nine applications of an alternative material. A separate study published in September involving patients with large, complex Wagner grade 3 and 4 chronic wounds, including those with exposed bone showed Dermacell AWM helped heal or drastically reduce the size of the wounds within 16 weeks.

"Dermacell AWM has been rigorously studied in clinical settings and is supported by numerous peer-reviewed publications, including the largest-ever clinical trial of human ADMs for wound treatment," said Frederic Peycelon, LifeNet Health's Vice President of International Markets. "It is a powerful therapy that supports effective outcomes while also simplifying treatment by bringing wounds to closure in as little as one application."

LifeNet Health will feature Dermacell AWM at the VSICON Annual Conference Oct. 17-20 in Hyderabad, India. During the conference, Washington, D.C.-based clinician Zakee Shabazz, DPM, FACFAS, will present on his clinical experience with Dermacell AWM in the exhibit hall. Dr. Shabazz is board-certified in foot surgery and chief of podiatry at Innova Fair Oaks Hospital. A key opinion leader in his field, Dr. Shabazz has been focused for nearly 20 years on caring for patients with advanced podiatric techniques and technologies.

Dermacell AWM is backed by the technologies and relentless commitment to quality that have made LifeNet Health a global leader in regenerative medicine. LifeNet Health's rigorous screening and production processes ensure the safety and effectiveness of each graft, and patented Matracell decellularization technology. The result is a wound-treatment solution that offers unsurpassed efficacy with unrivaled safety.

About LifeNet HealthLifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world's most trusted provider of transplant solutions from organ procurement to bio-implants and cellular therapies and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to http://www.lifenethealth.org.

SOURCE LifeNet Health

http://www.LifeNetHealth.org

See the rest here:
LifeNet Health brings first clinically proven allograft-based biologic wound therapy to India - PRNewswire

DUBLIN--(BUSINESS WIRE)--The "United States Biobanks Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.

The country research report on United States biobanks market is a customer intelligence and competitive study of the United States market.

Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the United States market. Also, factors that are driving and restraining the biobanks market are highlighted in the study. This is an in-depth business intelligence report based on qualitative and quantitative parameters of the market.

Additionally, this report provides readers with market insights and detailed analysis of market segments to possible micro levels. The companies and dealers/distributors profiled in the report include manufacturers & suppliers of biobanks market in the United States.

Highlights of the report

The report provides detailed insights into:

1. Demand and supply conditions of biobanks market

2. Factor affecting the biobanks market in the short run and the long run

3. The dynamics including drivers, restraints, opportunities, political, socioeconomic factors, and technological factors

4. Key trends and future prospects

5. Leading companies operating in biobanks market and their competitive position in United States

6. The dealers/distributors profiles provide basic information of top 10 dealers & distributors operating in (United States) biobanks market

7. Matrix: to position the product types

8. Market estimates up to 2024

The report answers questions such as:

1. What is the market size of biobanks market in the United States?

2. What are the factors that affect the growth in biobanks market over the forecast period?

3. What is the competitive position in the United States biobanks market?

4. What are the opportunities in United States biobanks market?

5. What are the modes of entering United States biobanks market?

Key Topics Covered:

1. Report Overview

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

2. Executive Summary

3. Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.2.4. Challenges

3.3. PEST-Analysis

3.4. Porter's Diamond Model for United States Biobanks Market

3.5. Growth Matrix Analysis

3.6. Competitive Landscape in United States Biobanks Market

4. United States Biobanks Market by Products & Service

4.1. Equipment

4.2. Consumables

4.3. Services

4.4. Software

5. United States Biobanks Market by Sample Type

5.1. Blood Products

5.2. Human Tissues

5.3. Nucleic Acids

5.4. Cell Lines

5.5. Biological Fluids

5.6. Others

6. United States Biobanks Market by Application

6.1. Regenerative Medicine

6.2. Life Science Research

6.3. Clinical Research

7. Company Profiles

7.1. Manufacturer's & Suppliers

For more information about this report visit https://www.researchandmarkets.com/r/1phbdl

Read more:
United States Biobanks Market Prospects, Trends Analysis, Market Size and Forecasts 2019-2024 - ResearchAndMarkets.com - Business Wire

ORLANDO, Fla., Oct. 18, 2019 /PRNewswire-PRWeb/ -- The Laser Institute (LIA)'s 38th International Congress on Applications of Lasers & Electro-Optics (ICALEO) was recently held in Orlando, Florida and featured the conference's many firsts. A meeting of laser industry experts and decision-makers from around the world, the event hosted dialogue with a deeper industry foci, more expansive technical sessions, and a new Business Conference that addressed laser end-users while highlighting solutions from the manufacturing community.

A collection of Live User Solutions Forums, Market Drivers Symposia, and Live User Solutions Round Tables discussions, the Business Conference acted as a complement to ICALEO's traditional Technical Conference. Regarded as a concentrated effort of participants from the Aerospace, Biomedical, Microelectronics, and Automotive industries, ICALEO's Business sessions allowed laser manufacturers, integrators, and end-users to engage in the discussion on the unique challenges and revolutionary applications in the industry.

To further emphasize the attendee-friendly approach of this year's ICALEO format, the Business Conference also presented a four-day tradeshow that connected all members of the laser marketplace. An accomplishment at dedicating whole days to each of its selected industries, the tradeshow hosted over 40 international exhibitors from the likes of IPG Photonics, II-VI, and more.

Spanning the duration of the conference to maximize the attendee's opportunity to network with these leading brands, the assembly of exhibitors also included Han's Laser Smart Equipment Group (ICALEO's Diamond Sponsor), Coherent Inc. (ICALEO's Platinum Sponsor), as well as TRUMPF Inc., Kentek, and Edgewave (ICALEO's Gold Sponsors).

Meanwhile, the ICALEO Technical Conference enhanced its focus on the innovative and novel uses of lasers and photonics via its subdivided tracks. These are comprised of the Laser Additive Manufacturing, Laser Materials Macroprocessing, Laser Materials Microprocessing, Laser Nanomanufacturing, and Battery Systems and Energy Conversion tracks.

An approach that allowed the conference speakers to deliberate on how laser applications can push the envelope of modern technology while advancing key industries in their accuracy, efficiency, and speed, the Technical Conference's new format also gave engineers and materials processing experts the chance to discover new processing techniques, acquire new skills, and collaborate to ensure their organization stays up-to-date and on the leading edge of productivity.

These innovations and advancements were envisioned in the opening addresses of the plenary speakers from all four industries. Peter Boeijink of XYREC opened the aerospace-focused conference with his speech on "The Largest, Highest-Power, Mobile, Industrial, Laser Materials Processing Robot in the World" while Dr. Christoph Leyens from Fraunhofer IWS discussed the "Innovative Aerospace and Space Structures Made by Additive Manufacturing."

Similarly, the esteemed Professor William Steen presented his speech "The Coming of the Age of Optical Engineering" during the biomedical conference, alongside Fraunhofer Institute of Laser Technology (ILT)'s Dr. Nadine Nottrodt who spoke on "Laser in Biofabrication How Laser Technology Can Help to Build Artificial Tissue." They were joined by Dr. Chris Bashur of the Florida Institute of Technology who elaborated on the "Photonic Needs in Regenerative Medicine."

Participants from the microelectronics industry mulled over the words of Dr. Kumar Patel of Pranalytica Inc. during his plenary speech on "Recapturing the Excitement of High Power Infrared Lasers," while Dr. Markus Arendt of SUSS MicroTec Photonic Systems spoke on the "Excimer Laser Ablation for High-Density Routing in Advanced Packaging."

During the automotive-focused conference, Ethan Sprague from the University of Michigan presented his thoughts on "Laser Aided Manufacturing: Atom to Automobile" before Dr. Ted Reutzel of Pennsylvania State University described the "Progress Towards Sensing and Mitigating Flaw Formation in Powder Bed Fusion Additive Manufacturing." Their presentations joined the observations on "Bottoms Up Digital Design: The Quiet Revolution of the Additive Manufacturing Age" by Dr. Jason Carroll of Eaton, a power-management company that provides energy-efficient solutions to managing electrical, hydraulic, and mechanical power.

To view the highlighted content from ICALEO 2019, including recorded interviews, panels, and speeches, follow LIA's social media profiles on Facebook, Twitter, and LinkedIn. The 39th ICALEO will be held at the McCormick Place Convention Center in Chicago, Illinois USA from Oct 19, 2020Oct 22, 2020. Call for papers and Tradeshow booth bookings will be made available soon, and interested parties may contact icaleo@lia.org for further information.

SOURCE The Laser Institute

Here is the original post:
Future of Laser Innovations Reflected at Revamped ICALEO Conference - Benzinga

Post-mortem scans of injured brains are causing researchers to question the hypothesis that blunt force trauma from traumatic brain injuries (TBI) causes nerve damage.

The scans, conducted by a team including researchers at the New York-based Cold Spring Harbor Laboratory (CSHL), have shown greater signs of blood vessel damage than nerve damage, and could influence how drugs are developed and treatments are implemented for TBI.

CSHL professor Partha Mitra said: Nerve damage following traumatic brain injuries has been a majority point of view, and therapy as well as drug development has been targeted towards that.

The idea is that if the mechanism is actually different, therapeutic intervention may also be different.

The CSHL team performed close analysis on post-mortem brain tissue using a high-throughput neurohistological pipeline, an assemblage of techniques for labelling and visualising brain slices, which Mitra had developed to study mouse brains.

Scanning the brains in this way provides much clearer images than magnetic resonance imaging (MRI) alone. While MRI can show clinicians that brain damage has occurred, the resolution is limited and it can be hard to discern whether nerve or vascular injury has occurred.

Correlating neurohistological pipeline scanning with MRI scans allowed the team to see the vascular injuries more clearly.

The researchers focused on areas surrounding lesions where trauma had left a physical impact on the brain, which appeared on the MRI scans as black spots.

They then used an iron stain to test for the presence of blood and a myelin stain to test of the presence of nerve fibre fragments in the brain samples. While a significant amount of iron-marked stains appeared in the brain samples in these areas, indicating traumatic microbleeds in the tissue, the researchers did not find any significant nerve damage from the myelin stains.

The researchers concluded that traumatic vascular injury is distinct from nerve damage and could thus be a target for new therapies. They also found that these traumatic microbleeds could often predict future health problems and disabilities for people with TBI, although they could not determine their relationship with acute problems.

The study has been published in the neurology journal Brain.

The team now hopes to conduct research into the underlying causes and effects of TBI for better diagnosis, prognosis, therapeutic targets and patient outcomes.

CSHL worked with colleagues at the National Institutes of Health, National Institute of Neurological Disease and Stroke, University of Maryland, Center for Neuroscience and Regenerative Medicine, and Uniformed Services University of the Health Sciences, which had been studying the brains of deceased patients using MRI.

Enter your details here to receive your free whitepaper.

Close survey

Close

Read the original:
Nerve damage not the root cause for symptoms of traumatic brain injury - Medical Device Network

In 2006, Shinya Yamanaka shook stem cell research with his discovery that mature cells can be converted into stem cells, relieving a longstanding political-ethical blockage and throwing open medical research on everything from curbing eye degeneration to organ printing.

But that process still has pitfalls, including in risk and scalability, and some researchers are exploring another way first hinted at years ago: new technology to convert mature cells directly into other mature cells without the complex and time-consuming process of first making them into stem cells.

One of those companies, Mogrify, just raised $16 million in Series A financing to bring its overall funding to over $20 million since its February launch. Led by CEO Darrin Disley, the funding will help expand their new base in Cambridge to a 60-strong staff and push forward their direct-conversion approach to cell therapy through research and licensing. Investors include Parkwalk Advisors and Ahren Innovation Capital.

They list potential applications as treatments for musculoskeletal and auto-immune disorders, cancer immunotherapy, and therapies for ocular and respiratory diseases. For example, you could use it regenerate cartilage in arthritis patients.

If you could take a cell from one part of the body and turn it into any other cell at any other stage of development for another part of the body, you effectively have the Holy Grail of regenerative medicine, Disley told Labiotech.eu in April.

Mogrifys advantage over the Yamanaka method called induced pluripotent stem cells (iPS), is that in theory it can be more scalable and avoid the problems associated with iPS. These include instabilities arising from the induced immature state and an increased risk of cancer if any pluripotent cells remain in the body.

The concept behind Mogrify actually predates, by nearly 19 years, Yamanakas discovery, which fast won him the 2012 Nobel Prize in Medicine. A 2017 Nature study on transdifferentiation, as the process is called, of fibroblasts into cardiac tissue traced the idea to a 1987 findingthat a master gene regulator could convert mice fibroblasts into skeletal muscle.

The problem though, according to Mogrify, is that most current efforts rely on an exhausting guess-and-check process. With hundreds of cell types and an even greater number of transcription factors the program that recodes the cell finding the right factor for the right cell can be like a custodian with a jangling, unmarked key ring trying to get into a building with thousands of locks.

Mogrifys key tech is a computer model they say can predict the right combination. The scientists behind the platform published a 2016 study in Nature applying the model to 173 human cell types and 134 tissues.

Before Mogrify, Disley led the Cambridge-based gene-editing company Horizon Discovery.

Originally posted here:
Cell therapy startup raises $16 million to fund its quest for the Holy Grail in regenerative medicine - Endpoints News

Delegates from the American Academy of Stem Cell Physicians recently traveled to the Bahamas to meet with the Governor General Sir Cornelius Alvin Smith to discus medical industry safety standards.

While in the Bahamas the delegates attended a 3 day regenerative health summit for educators, experts, professionals and learners where in doctors from all over the world arrived to discuss the future of regenerative medicine and stem cell therapy.

Dr. Krutchkoff announced the launch of the AASCPs Research Consortium dedicated to supporting research to validate therapies and promote compliance within the industry. During the HEALinc Summit Dr. Farschian and Dr. Krutchoff, the American Academy of Stem Cell Physicians delegates, held a workshop to teach physicians about a pathway to compliance when utilizing cell therapies in their practices.

The AASCP was created to advance research and the development of therapeutics in regenerative medicine, and aims to serve as an educational resource for scientists, physicians, and the public in diseases that can be caused by physiological dysfunction that are ameliorable to medical treatment.

The HEALinc Summit was organized by Dr. Desiree Cox, CEO of the HEALinc Future of Health Innovation Summit and The HEALinc Innovation Incubator which is a movement based organization with a mandate to champion a future health paradigm where medical therapy is driven by personal health and regenerative medicine by incorporating ongoing, real world capture, predictive analytics, and education.

Dr. Cox currently chairs the National Stem Cell Ethics Committee for the Bahamas, and has been leading health innovation and the development of the stem cell and regenerative industry since 2015 in the Bahamas which is a fast track test bed for real world studies in stem cell, regenerative medicine, and medical devices among others.

During the HEALinc Summit leading international experts spoke on hot topics in stem cell therapy, longevity and vitality, regeneration, resilience and adaptability, precision health, epigenetic and nutrition, personal wellness and optimal health, regenerative ventures/investment and much more.

"Within the Bahamas, health innovations in cellular and gene therapies, regenerative medicine, precision medicine and digital health can be tested ethically and safely in a regulated environment, so that the data obtained from the research can be used in later applications for FDA or EMA approval, says Dr. Cox.

Dr. AJ Farshchian, spokesperson for AASCP said, "It was a great honor meeting the Governor General in the Bahamas. We discussed safety standards currently practiced in the industry and how to improve the industry moving forward."

Dr. Adam Shwani, a member of the board for the American Academy of Stem Cell Physicians, added, "It is so important to bring industry partners together from all over the world to develop a standard that promotes patient safety and encourages growth in the field of regenerative medicine.

Go here to see the original:
AASCP Delegates Meet With The Governor General Of The Bahamas - Anti Aging News

Enso Discoveries is proud to partner with the Kansas Department of Agriculture for the fourth year to bring the veterinary and agricultural industries in the midwest the Kansas Veterinary Regenerative Symposium as part of the Kansas Veterinary Medicine Association Annual Meeting.

MANHATTAN, Kan., Oct. 17, 2019 /PRNewswire-PRWeb/ -- Enso Discoveries, the perennial sponsor of the Kansas Veterinary Regenerative Symposium (KVRS), proudly announces the 4th annual session hosted by the Kansas Department of Agriculture (KDA) on the second day of the Fall Kansas Veterinary Convention & Kansas Veterinary Medicine Association (KVMA) Annual Meeting happening in Manhattan, Kansas from November 8-10, 2019.

The Fall Kansas Veterinary Convention promises over 40 hours of quality education in small and large animal medicine, practice management and veterinary technicians. Speaking sessions, wet labs and workshops offer practical information, flexible schedule, networking and more over the three-day event.

"The mission of the KVRS has always been to concisely educate the practicing veterinarian about regenerative medicine in such a way that they can immediately implement into their practice. Once a treatment option available only to a limited few, it is now available for most every patient, so being informed has never been more important," said Corey Orava, DVM, CSO of Enso Discoveries and Chair of KVRS.

This year KVRS will have four speakers from both academia and private practice. The general theme of the Symposium will be regenerative therapies in veterinary medicine with topics including Platelet Rich Plasma and Platelet Rich Fibrin in both large and small animal practice:

Date: November 9, 2019 Time: 1:30 PM Location: Hilton Garden Inn & Conference Center Address: 410 S. 3rd Street, Manhattan, KS 66502

"Using the body to heal itself is the perfect marriage of natural and advanced technology. It is truly a marvel to witness the progress of my patients. I can't say enough about Enso Discoveries and the easy-to-use kits we now use to offer PRP as a service to our clients." - Kendell Michel, DVM, CVCP, Family Animal Care of Salina, Kansas

### Our mission at Enso Discoveries is to greatly enhance the lives of animals through the development of cutting-edge, novel technology. We believe all things are possible. We offer a wide range of innovative services, university-backed science, and affordable medical products with an emphasis on regenerative medicine.

We continually perform and fund veterinary research with the help of our academic and industrial research partners. While maintaining the highest level of integrity, we continue to succeed because we support our products and services with scientific proof, superior sales and marketing ability, and a worldwide network of industry experienced contacts.

Visit link:
Enso Discoveries and Kansas Department of Agriculture will Host the 4th Annual Kansas Veterinary Regenerative Symposium on Saturday, November 9, 2019...

Nassau, The Bahamas The best and brightest global recently gathered in The Bahamas to discuss ways of making stem cell and regenerative health technologies available, accessible and affordable to everyone, everywhere.

Dr. Desiree Cox, Rhodes Scholar and Founder and CEO of HEALinc reflects, This event promotes research and innovation in medical technologies with the potential to help people stay healthy through their lifespan. Our presenters and sponsors delivered an immersive experience that bridged the gaps between modern regenerative medicine technologies and ancient healing arts of creativity, music, movement and breathwork.

The second annual HEALinc Future Health and Innovation Summit was hosted at the Grand Hyatt, Baha Mar Convention Center from October 2 4, 2019 with an audience of more than 200-participants. A slate of more than 50 presenters delivered thought-provoking presentations and the celebrity keynote speech was given by Dr. Joe Dispenza,an international lecturer, researcher and author who has been invited to speak in more than 33 countries on six continents. Dr. Dispenza challenged the audience to rewire the brains and recondition their bodies to make lasting life changes.

Dr. Steven Greco, Chief Scientific Officer of the Houston Healthspan Innovation Group said, Regenerative medicine and immune restoration treatments provide safe, accessible options for patients. Houston Healthspan was pleased to share some of the exciting pilot data related to orthopedic and neurological treatments delivered at Okyanos. Through our participation and the sponsorship of the Bosarge Family Foundation, we were able to collaborate on this Summit because of our shared commitment to HEALinc., and to The Bahamas.

Dr. Joshua Hare, Professor of Medicine at University of Miami and Co-founder and Chief Scientific Officer of Longeveron, presented important scientific data from Longeverons multiple FDA authorized stem cell trials in the US as well as the 60+ patients treated in The Bahamas in Longeverons approved open Registry for aging and musculoskeletal related disorders.Dr. Todd McAllister, CEO of Fountain Therapeutics scheduled to begin operations in Bimini was a keynote speaker at the Summit along with Dr. Robert Hariri, Founder and President of Celularity, and one of the angel investors of Fountain Therapeutics along with Peter Diamandis and Tony Robbins. Dr. Hariri says, This Summit is an ideal environment to engage in conversations that affirm our commitment to harnessing the powerful biology of the placenta to treat cancer, immunological and degenerative diseases and we commend Dr. Cox for her leadership in this regard.

Dr. Cox says, As we grow, we anticipate hosting events in the United States that provide a space for more individuals to showcase products and services that will allow more persons to live longer, healthier and happier lives because of the integration of modern and ancient regenerative health technologies.

Continued here:
Second annual Regenerative Medicine summit proves big win for The Bahamas - EyeWitness News

TOKYO--(BUSINESS WIRE)--Utilizing the capability of ones own immune system to tackle cancer, an out-of-the box idea was the brain child of Dr. Steven Rosenberg almost three decades ago. His initiative which paved way for a new chapter in oncology, inspired many young scientists and clinicians in the NCRM NICHE 2019 held in Tokyo, Japan, as his acceptance speech in the Edogawa NICHE Prize ceremony was videocast.

NCRM NICHE, an active knowledge gaining academic event since 2006 in which young scholars from all over the world compete for the Fujio Cup Quiz (FCQ) in regenerative medicine is evolving to be an open innovation platform according to Dr. Shojiro Katoh, Chairperson of Edogawa Evolutionary Lab of Science (www.eels.tokyo), a co-host. He added that the FCQ motivated his team research on 16 different themes in Regenerative Medicine in various clinical specialties, among which two have completed clinical pilot studies with successful outcome viz., corneal endothelial regeneration and urethral stricture repair.

The XIV edition of FCQ contest that witnessed teams from Malaysia, Indonesia and India in the finals, was won by Reshma Romanas and Aayurshi Agrahari of Kasturba Medical College, India. Alumni of the FCQ are now eligible to nominate the awardees for Edogawa NICHE Prize which was established in 2018 to honour scientists or clinicians who develop novel solutions in healthcare, based on inter-disciplinary interactions. Dr. Steven A. Rosenberg, Chief of surgery, National Cancer Institute, NIH, USA is the recipient of the award in 2019. The award portrays such accomplished role models to the FCQ Elites according to the organizers who have instituted Joyce & James Till Travel Grant with a generous grant by Prof James Till, that supports travel of yesteryears FCQ Elites, who are now accomplished researchers in their own rights to meet and inspire the FCQ Elites of today, thus bringing together science and generations across nations.

NCRM NICHE is supported by a consortium with EELS as knowledge partners and JBM Inc., as industry partners based in Tokyo which has set up a hybrid cell culture cum biomaterials lab for taking forward the cell therapy and tissue engineering innovations to bed side, with future plans to propagate them globally through networking with like-minded academic and industry partners.

Originally posted here:
Accomplishments of Dr. Steven Rosenberg in Cancer Immunotherapy Inspire Young Researchers in Japan & XIV Fujio Cup Quiz on Stem Cells Is Won by...

Alexis Nolfi went to her doctor one day to get treatment for her dry eyes.

Nolfi, a graduatebioengineeringstudent researcher in the University of PittsburghsSwanson School of Engineering, has been dealing this condition for several years now and the eye drop treatments she had been taking were only working temporarily, so she was using eye drops multiple times a day.

Its been pretty frustrating and borderline debilitating, said Nolfi. I had been using artificial tears every night and all through the day. I still use them all the time and havent been getting adequate relief, and I fight with my insurance company to cover prescription eye drop treatments.

However, this 2018 visit to her eye doctor,Vishal Jhanji, would be different.

While talking with each other in the doctors office, they realized the need for better treatment options for dry eye syndrome, which affects millions of Americans each year.

Dry eye is the most common reason patients come into our office, said Jhanji, a professor ofophthalmologyin PittsSchool of Medicine. She (Nolfi) had been using eye drops 10 to 15 times a day.

Nolfi then decided to experiment with contact lenses given to her by Jhanji to develop a new therapy tool and drug delivery system to target inflammation that can cause this irritating condition. What came out of it was the CyteSolutions Lens, a silicone-hydrogel-based contact lens coated with natural biopolymers organic molecular structures containing adrugthat targets inflammatory dry eye pathways not targeted by any other current treatments.

The coating is only activated and degraded whenever it makes contact with the surface of your eye, because there are enzymes in your eyes that work to degrade the polymers we use, said Nolfi. This allows the slow and safe release of drugs over a period of hours or even days as opposed to drops that almost immediately fall out of or drain away from your eyes.

While contact lens-based therapies have been previously developed by dipping lenses in drug solutions, the team is using biopolymers for slow and sustained drug delivery to target the inflammatory pathways in the eye.

There is a definite need for innovation and ways to deliver drugs to the surface of the eye, Jhanji said. Were not looking to simply replenish the eye; were trying to tackle the root cause of this problem.

Nolfi and Jhanji, along with Swanson School researchersMangesh KulkarniandBryan Brown, recently won one of three $100,000 grand prizes at the 2019 Pitt Innovation Challenge, hosted by Pitts Clinical and Translational Science Institute, to further advance their innovation.

Jhanji said dry eye syndrome has become more common in the 21stcentury, and with that has come more treatment options, ranging from over-the-counter eye drops to surgery depending on the patient.

The CyteSolutions Lens team wishes to eventually take their prototype to clinical trials and will ramp up studies thanks to the competitions funding. The researchers said anyone who uses contact lenses would be good candidates to try CyteSolutions Lens.

We dont expect this lens to feel any different from standard soft contact lenses, and theyre natural with no chemical crosslinking, said Jhanji.

PittsInnovation Institute, theMcGowan Institute for Regenerative Medicineand the UPMC Eye Centerassisted with research on the CyteSolutions Lens.

Continued here:
Researchers See Future of Dry Eye Treatment in Innovative Contact Lens - UPJ Athletics

MANCHESTER Now that the world has the Impossible Whopper, will the impossible liver be far behind?

Such possibilities are being broached this week as inventor Dean Kamen, founder of the Advanced Regenerative Manufacturing Institute, hosts the fourth semi-annual summit since launching ARMI in July 2017.

The three-day conference started Tuesday with a members-only day for BioFab USA and ARMI. It included a dinner at Kamens Bedford home.

Two public days of speeches and workshops are scheduled through Thursday. A total of 150 have signed up for the event.

Guests listen to a speaker at the Meeting in the Millyard at ARMI in Manchester on Wednesday, Oct. 16, 2019.

The keynote speaker on Wednesday was Jason Kelly, co-founder and chief-executive of Ginkgo Bioworks, a synthetic biology company that programs cells for customers in the chemical, pharmaceutical, food and energy industries.

We program cells because they run on digital code in the form of DNA, Kelly told a crowd of scientists, entrepreneurs and regulators.

Much of ARMIs work has focused on the use of stem cells to generate replacements for human tissue, bones and organs. For example, one of ARMIs biggest accomplishments to date has been the Tissue Foundry; its first production was bone-ligament tissue grown together from bone-marrow stem cells.

But Kamen, who prides himself on introducing new technologies to a field, had Kelly speak about a different kind of cells synthetic cells.

Ginkgo Bioworks has partnered with Bayer to develop self-fertilizing crops, with Roche to develop antibiotics, and with Motif to produce animal-free protein ingredients. Kelly said synthetic cell production played a role in the Impossible Whopper, the plant-based patty that Burger King claims tastes like beef.

(According to the website of Impossible Food, the company that makes the patty, the company extracts DNA from soy plants and inserts it into genetically engineered yeast, which ferments to produce heme, the molecule that gives meat its taste.)

Ginkgo has made CNBCs Disruptor 50 List in the last three years and recently raised more than $430 million in venture capital. In doing so, Ginkgo has achieved what Kamen wants for ARMI to move from theoretical design and laboratory work to mass production.

Theyve learned how to scale it, Kamen said in his introduction. Kamen said he expects ARMI-linked production to start relatively quickly.

(Finding) talent is not the problem. Capital is the problem, Kelly said about tech startups. Many venture capitalists arent experts in the science-heavy world of what he calls tough tech. So they are wary about investing in something they cant grasp.

He advised startups to seek government grants Ginkgo would not have succeeded without them hustle the non-specialist investor and find third-party validation from agencies such as the FDA or the Standards Coordinating Body, a voluntary organization that sets standards for the regenerative medicine industry.

Kelly said the time is now for tough tech. He noted the work of SpaceX and Tesla, and he said Silicon Valley is embracing biotech.

People have run out of things to invent that end up as a square on your phone, he said.

Go here to read the rest:
ARMI summit: With synthetic meat within grasp, why not synthetic liver? - The Union Leader

The regenerative medicine market is predicted to develop at a CAGR of 25.4%, driven by the growing cell-based immunotherapy sector.

Cell therapies are the major driver behind the growth and will leap from being worth $13.2 bn in 2019 to $45.7bn in 2026 resulting in a compound annual growth rate (CAGR) of 23.8%, according to a Acumen Research and Consulting report.

In terms of causal reasons for the growth, the demand for such therapies is fuelled by a global ageing population and the rising incidence of cancer.

As a result, oncology has become a major therapeutic focus for companies with over a third of the current cell and gene therapy pipeline orientated toward finding a treatment for cancer.

Get Free Sample Copy@ https://www.acumenresearchandconsulting.com/request-sample/337

However, the specialist treatments often come with a higher price tag, compared to traditionally developed treatments, and as such, the highest growth will be seen in countries with growing health care sectors and those with populations that have the highest disposable incomes.

The niche within cell therapies that is seeing particularly high investment is chimeric antigen receptor (CAR)-T therapies, which has seen two treatment approvals in the US and Europe. In addition, there are number of other CAR-T therapies currently in clinical trials globally.

The development of the area has led to a number of acquisitions taking place in the sector, such as Gileads takeover of Kite, to gain access to its CAR-T treatment, and Novartis acquiring CellforCure to expand its manufacturing network for cell and gene therapies.

Despite the highest growth seen in the oncology sector, the overall largest market is for muscoskeletal disorders. This is due to the rise of orthopaedic diseases and injuries related to a rising geriatric population.

Geographically, the North American region accounts for the largest share of the regenerative medicine market.

Editor-in-Chief

20+ years of diverse and extensive experience in higher education including teaching, research, and university and community service in overseas universities and colleges.Associate Editor, and publications in international refereed journals and presented most of them in international conferences in the fields of Applied Multivariate Statistics, Mortality, Social Science, Economics.

Mail: globalqyresearch@gmail.com

Follow this link:
Regenerative Medicine Market Predicted to Develop at a 23.8% of CAGR - Story of Future

Companies that reject shareholder primacythat prioritize the needs of society, community, consumers, and employees above shareholder valueand those that fully understand the social and environmental impacts of their entire supply chain, irrespective of product or industry, will be the ones to thrive.

Companies that reject shareholder primacythat prioritize the needs of society, community, consumers, and employees above shareholder valueand those that fully understand the social and environmental impacts of their entire supply chain, irrespective of product or industry, will be the ones to thrive.

To define the characteristics of those companies: They will demonstrate emotional intelligence, flexibility, and the ability to adapt to complex, quickly-shifting conditions, work forces, and social movements. The companies that develop innovative products and services designed to protect people from climate impacts (sea-level rise, extreme heat, disaster) will prosper as well. Examples are companies that make cooling vests for outdoor workers, police officers, and firefighters; flood-response companies; design firms that build resilient structures capable of floating or adapting to rising waters; even private extraction companies like those being used by oil and gas entities to extract personnel from harmful situations like political conflicts, violence, or natural disasters.Further, companies with a majority of women on their boards and executive teams will outperform competitors and lead in their industry. In fact, I would venture that the numbers of men will flip to a women-led majority in most everything in the next 50 years.

Finally, given the increase in both the types of risk and the size of risk exposures such as hurricane, drought, extreme heat, and floods, property and casualty industry will finally transform. Along with reinsurance companies, they will offer individual policies that pay quickly based on a metric such as wind speed or sustained temperature.

More:
What will the world look like in 50 years? - Quartz

The biofabrication race is on. Scientists around the world are competing and the rise of biotechnological commercial players has diversified the field, moving fast to keep up with high expectations from scientists, healthcare providers and pharmaceutical companies eager to take the research to clinical therapy. But this is no easy transition, and even though bioprinting has moved the field forward, it is not as close to patients as everyone hopes it would be. One new company is now bringing a different message, one of possibility and hope that could pave the way for the future of healthcare.

Newly launched mimiX biotherapeutics is developing the next generation of biofabrication solutions to provide Point-of-Care tissue engineering for regenerative, personalized and precision medicine. Founded by Marc Thurner, who just this year left his previous creation regenHU and is now beginning a new chapter in his life, the startup will commercialize a new bioprocessing technology called Sound Induced Morphogenesis (SIM). Off to a new start, Thurnernow the CEO of mimiX biotherapeuticsspoke with 3DPrint.com about the scientific tool he expects could revolutionize regenerative medicine and diagnostics, and which he expects to launch commercially by next summer.

Could we accelerate the biofabrication revolution in the healthcare industry? wondered Thurner back in June.

This is a big question and one which he believes to have found the answer.

Just after I left regenHU, I began touring the countryside with my family. But I quickly went from a camping experience to a new tech venture. Tiziano Serra (the inventor of 3D-SIM technology) came to see me claiming he had an interesting technology in the field of biofabrication. After spending a week looking over some of the amazing scientific results and data he had developed throughout the last six years I decided this was an opportunity I couldnt miss, revealed Thurner. At the time, I realized that the technology most of the bioprinting companies have, which are based on conventional extrusion systems, are a great tool for scientific research but will probably never make the translation into the clinical environment, he revealed.

Marc Thurner

Instead, mimiX biotherapeutics technology has already demonstrated with scientific evidence that it offers tissue engineering strategies to overcome todays obstacles, for example, the creation of dense networks of cell suitable for micro vascularization.

According to Thurner, bioprinting using conventional dispensing systems is good for science but much too complicated for clinical use due to several critical hurdles including scalability, affordability, manufacturing, and because they entail complicated and labor-intensive processes.

He also claims that the current cell therapy available is costly and time-consuming since patients own biopsies are sent to labs where cells are isolated and amplified to create artificial tissue using 3D printing (or other more conventional methods) so that they can weeks later be transplanted back into the patient. It just takes too long.

It seems clear that we need to overcome this rudimentary process which is not stable and a logistical nightmare. Instead, mimiX biotherapeutics opens the door to manufacturing patient-specific tissues directly in the operating room (OR), enhancing patients autologous biological materials, for their own treatment. So, we see an opportunity to reduce the cost of the tissue engineering procedure. Moreover, we hope that in the future, most medical practitioners will be able to use the patients own biological material to process it directly in the OR without the need of any specific expertise in engineering or robotic tools required by typical bioprinters.

Delivering their technology to the clinical environment is the ultimate goal for the startup, which is headquartered in Neuchtel, Switzerland. Thurner hopes that one day every hospital will have a 3D-SIM system in the OR, to enhance the biomaterial that they obtain from the patient, and create tissue that is ready to be implanted within a few minutes.

Thurner went on to say that this could be possible within a timeframe of 10 years because we are simplifying the process and because the materials dont have to go out of the OR. This means that beyond patient care, we are also offering a solution to one of the biggest problems the healthcare industry has: extremely high costs.

Tiziano Serra

The 3D-SIM technology behind mimiX biotherapeutics is nearly a decade old. It was developed by Tiziano Serra, a Research Scientist at the AO Research Institute in Davos, Switzerland, with the objective of creating well-defined biological patterns that self-assemble into functional tissues using sound waves. A process Serra has poetically defined as orchestrating biology. The company states that SIM is a cell and biologics patterning process to create a 3D biological template in which cells induce morphogenesis through a self-assembly mechanism. SIM technology offers a highly efficient strategy creating dense and organized cell patterns.

The beauty behind SIM is that Serra began exploring its potential many years ago and already understands which type of patterns induce different types of tissue engineering strategies. Our current focus is on micro vascularization, which is the big bottleneck in regenerative medicine.

Our universe is immersed in waves, and mimiX biotherapeutics machines transmit them. A proprietary Labware is first placed on a type of speaker and depending on the sound emitted, the waves that are generated transmit energy to the labware and the cell-cultured media. The cells will then be patterned in different forms, such as circular, square, star shape or in agglomerates to trigger a self-assembly process. The company plans to deliver its novel instrument as a scientific tool next year for the research community, allowing them to explore the potential of what they could achieve when switching from conventional bioprinting to SIM. The small device fits any biosafety cabinet, and Thurner hopes that it will exponentially trigger the intellectual property behind the technology.

Marc Thurner

The company is driven by experienced healthcare, life science managers and scientists and benefits from cooperation with the AO Foundation, a nonprofit organization dedicated to improving the care of people with musculoskeletal injuries and their sequels through research, development, education and quality assurance.

Thurner has already begun setting up strategic partnerships to move forward with research and development, clinical trials, and luring strategic investors to join the venture. He is already preparing for a Series A round of financing to go to market with his prototype and start a clinical journey.

I am convinced we need to work with an open innovation mindset because the field of biofabrication is so versatile. To enable a revolution we need to bring together our expertise in hardware and software, along with cell therapy, clinical and healthcare knowledge. Even more so, our device will be an ideal lab instrument with the potential to be used in many fields, from biotechnology to drug discovery, concluded the expert.

Read more:
Marc Thurner Launches mimiX Biotherapeutics to Bioprint in the OR Using Sound - 3DPrint.com

SHANGHAI, Oct. 16, 2019 /PRNewswire/ -- Medtec China 2019, organized by Informa Markets, was successfully held at Shanghai World Expo Exhibition & Convention Center. It brought together 436 exhibitors from 25 countries and regions, including 150 first-time exhibitors; international exhibitors accounting for 56% of the turnout. The exhibition handled 28,057 visitors over three days, mainly professionals of R&D / Technology, Production / Manufacturing, Purchasing, Quality, Regulatory Affairs, and Senior Management from 41 countries and regions.

Industry leaders gather at a Medtec China that provides wide choice for procurement

Medtec China brings together and continues to attract leading medical device manufacturers from home and abroad, to exhibit a great many high-quality innovative technologies and products for the audience, thereby meeting the ever-increasing needs in the medical market.

Tekni - Plex, Suzhou Bank Valley, Baoji Xinuo, DuPont and other material suppliers exhibited Cellene thermoplastic elastomeric particles, medical absorbable biodegradable polymer materials, medical titanium, and the new packaging material Tyvek 40L; Delta Precision, Shanghai Y&L, Gowin Mold, and other enterprises exhibited high-precision and micro-machinery parts, holistic processing and manufacturing systems, and hot runner systems; JoyMed Technology and JCBIO are committed to providing a full range of commissioned product development, clinical, registration and OEM services for small and medium medical device enterprises and clinical institutions around the world. Medical automation device providers, such as Mikron, Team Technik and KAHLE Automation SRL, provide reliable assembly and testing lines for complex products, including POC diagnostic equipment, self-service pen injectors, dialysis filters, inhalers, infusion apparatus, insulin pens, pre-filled syringe, safe indwelling needles, and infusion tubes.

Conferences and forums following the industry focus, full house onsite

Chinese Regulatory Updates and Compliance, the 7th IIMD China Summit, Risk Management of Medical Product Life Cycle, MDR's MDSAP, and MDSAP&QSIT inspection all took place during Medtec to heightened interest. Lin Feng (Director, Medical Device Registry at Shanghai Food & Drug Administration), Feng Xiaoming (Deputy Director, National Institutes for Food and Drug Control (NIFDC) Biomaterials and Tissue Engineering Office), Xi Tingfei (Director of the Medical Device Inspection Center of the China National Institutes for Food and Drug Control), Shao Linyun (Deputy Director of the Central R&D Management Department of Shenzhen Mindray), William Sutton (Assistant Director in the Office of International Programs (OIP) at the United States Food and Drug Administration (FDA) China Office), and other authoritative speakers appeared to present speeches.

Medtec China this year continued to introduce the technology development forum on new medical dressings. Qin Yimin (Director of State Key Laboratory of Bioactive Seaweed Substances) was invited to introduce the properties and applications of silver-containing wound dressings, and Hu Fang (Board Chairman, Bestlife Regenerative Medicine) shared their insights on the selection and use of raw materials in the development and design of new high-end medical dressings.

Overall, there were 15 keynote forums covering 65 sessions of lectures; 53 invited speakers appeared to speak and share; and more than 1,500 industry representatives participated in the onsite events.

Medtec China 2020 will be held againfrom September 1416, 2020. High-quality brand suppliers from nearly 25 countries around the world will offer design, raw materials, precision parts, manufacturing equipment, processing technology, contract customization, testing and certification, policies and regulations, market consulting and other services required for product development, production and registration. It is expected to be attended by more than 30,000 visitors. A wealth of onsite events will offer premium opportunities for visiting and learning. For more information, please visit http://www.medtecchina.com.

Contact Us:Carina LiTel: +86-10-5730-6163E-mail: carina.li@ubm.comMedtec China Organization Committee

View original content to download multimedia:http://www.prnewswire.com/news-releases/medtec-china-2019-successfully-rounds-off-upgrading-to-two-pavilions-in-2020-to-power-innovative-development-of-chinas-medical-device-industry-300939535.html

SOURCE Medtec China

Read the original post:
Medtec China 2019 successfully rounds off; upgrading to two pavilions in 2020 to power innovative development of China's medical device industry -...

Heart failure remains the leading cause of mortality in the U.S. During a heart attack, blood stops flowing into the heart. Without oxygen, part of the heart muscle dies. The heart muscle does not regenerate, instead it replaces dead tissue with a scar made from cells called fibroblasts. If there is too much scarring, the heart progressively weakens. A large proportion of people who had a severe heart attack will develop heat failure and scarring in the heart.

One of the interests of my lab is to develop ways to heal heart muscle by studying cellular pathways involved in heart development and regeneration, said Dr. James F. Martin, professor and Vivian L. Smith Chair in Regenerative Medicine at Baylor College of Medicine and director of the Cardiomyocyte Renewal Lab at the Texas Heart Institute.

In previous studies, Martin and his colleagues discovered that inactivating the Hippo signaling pathway in adult murine hearts triggered cardiac muscle cell regeneration after heart attack. These findings raised hope for the development of promising heart failure therapies involving the Hippo pathway.

In the current study, Martin and his colleagues further investigated the Hippo pathway in the adult murine heart, this time focusing on its role in cardiac fibroblasts, non-muscle cells that are closely associated with cardiac muscle cells. The researchers conducted a number of basic studies, including single cell sequencing experiments that provided a high level of resolution to their analyses.

We inactivated the Hippo pathway in resting adult hearts that did not have any injury and observed that the fibroblasts became activated they proliferated and developed into myofibroblasts, a major cell type that appears in heart tissues after an injury, Martin said.

Mouse hearts with a deficient Hippo pathway in cardiac fibroblasts spontaneously developed cardiac fibrosis, even without injury, which resulted in severe heart dysfunction, said co-first author Dr. Yang Xiao, who was a postdoctoral fellow in the Martin lab during this project. This and other evidence indicated that the Hippo pathway is required to restrain cardiac fibrosis; Hippo is important for maintaining the fibroblasts in their resting state.

In addition, the researchers found that inactivating the Hippo pathway also triggered a molecular cascade resulting in an inflammatory response that was mediated by Yap, a molecule that regulates a number of molecular pathways.

We know that Hippo and Yap work together. Hippo acts like a brake for Yap, so when we took away Hippo, Yap remained active and regulated the expression of important signaling molecules that talk to macrophages and other immune cells luring them into the heart, Martin said.

The researchers believe they have identified important insights into heart function. Their findings inform about the genetic pathways that are important for maintaining the fibroblasts in their resting state.

Find the complete article in the journal Genes & Development.

Other contributors to this work include co-first author Matthew C. Hill, Lele Li, Vaibhav Deshmukh, Thomas J. Martin and Jun Wang. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, the Texas Heart Institute and the University of Texas Health Science Center at Houston.

This study was supported by grants from the National Institutes of Health (DE023177, HL127717, HL130804, HL118761; F31HL136065; K01DE026561); American Heart Association (14SDG19840000), Vivian L. Smith Foundation, State of Texas funding, Fondation LeDucq Transatlantic Networks of Excellence in Cardiovascular Research (14CVD01) Defining the genomic topology of atrial fibrillation. Further support was provided by Intellectual and Developmental Disabilities Research Center grant number 1U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and the Mouse Phenotyping Core at Baylor College of Medicine (U54 HG006348).

By Ana Mara Rodrguez, Ph.D.

Original post:
What the Hippo pathway in cardiac fibroblasts reveals about heart function - Baylor College of Medicine News

Spontaneous recovery from disease is often painted as superstition but our body can heal itself

It may come as a surprise to some, especially those with conventional medical training, but the default state of the body is one of ceaselessregeneration. Without the flame-like process of continual cell turnover within the bodylife and death ceaselessly intertwinedthe miracle of the human body would not exist

In times of illness, however, regenerative processes are overcome by degenerative ones. This is where medicine may perform its most noble feat, nudging the body back into balance with foods, herbs, nutrients, and healing energies and intentions.

Today, however, drug-based medicine invariably uses chemicals that lackregenerative potential; to the contrary, they commonly interfere with bodily self-renewal in order to suppress the symptoms against which they are applied.

In other words, most medicines attack disease symptoms rather than support the bodys own ability to combat disease.

Over the course of the past few years of trolling MEDLINE (the National Institutes of Healths website produced by the National Library of Medicine), we have collected a series of remarkable studies on a topic considered all but heretical by the conventional medical systemspontaneous remission.

There is actually a broad range of natural compounds with proven nerve-regenerative effects. A 2010 study published in the journalRejuvenation Research, for instance, found a combination of blueberry, green tea and carnosine have neuritogenic (i.e. promoting neuronal regeneration) and stem-cell regenerative effects in an animal model ofneurodegenerative disease.Other researched neuritogenic substances include:

There is another class of nerve-healing substances, known asremyelinatingcompounds, which stimulate the repair of the protective sheath around the axon of the neurons known as myelin. Myelin is often damaged in neurological injury and/or dysfunction, especially autoimmune and vaccine-induceddemyelination disorders.

It should also be noted that evenmusicandfalling in lovehave been studied for possibly stimulating neurogenesis, regeneration and/or repair of neurons, indicating that regenerative medicine does not necessarily require the ingestion of anything; rather, a wide range oftherapeutic actionsmay be employed to improve health and well-being, as well.

[To view the first-hand biomedical citations on these neuritogenic substances, visit GreenMedinfosneuritogenicresearch page online.]

Glycyrrhizin, a compound found within licorice that is also a powerfulanti-SARS virus agent, has also been found to stimulate the regeneration of liver mass and function in the animal model of hepatectomy. Other liver regenerative substances include:

[To view the first-hand biomedical citations, visit GreenMedinfosliver regenerationresearch page on the topic online.]

The medical community has yet to harness the diabetes-reversing potential of natural compounds. Whereas expensive stem cell therapies, islet cell transplants, and an array of synthetic drugs in the developmental pipeline are the focus of billions of dollars of research, annually, our kitchen cupboards and backyards may already contain the long sought-after cure for type 1 diabetes. Nature has a way of providing the things our bodies need.

The following compounds have been demonstrated experimentally to regenerate the insulin-producing beta cells, which are destroyed in insulin-dependent diabetes, and once restored, may (at least in theory) restore the health of the patient to the point where they no longer require insulin replacement.

[To view the first-hand biomedical citations onbeta cell regeneration, visit GreenMedinfos research page on the topic online.]

Secretagogues are substances in the body that cause other substances to be secreted, like sulfonylureas, which triggers insulinrelease. Secretagogues, includingsynthetic secretagogues, can increase the endocrine glands ability to secrete more of a hormone. But even better are substances thattruly regeneratehormones which have degraded. They do this by emitting electrons into potentially carcinogenic transient hormone metabolites. One of these substances isvitamin C.

A powerful electron donor, this vitamin has the ability to contribute electrons to resurrect the form and function of estradiol (estrogen; E2), progesterone, and testosterone, for instance. In tandem withfoods that are able to support the function of glandslikethe ovaries, vitamin C may represent an excellent complement or alternative to hormone replacement therapy.

Not too long ago, it was believed that cardiac tissue was uniquely incapable of being regenerated. A new and rapidly growing body of experimental research now indicates that this is simply untrue. A class of heart-tissue regenerating compounds, known asneocardiogenicsubstances, are able to stimulate the formation of cardiac progenitor cells which can differentiate into healthy heart tissue. Neocardiogenicsubstances include the following:

Another remarkable example of cardiac cell regeneration is through what is known as the fetomaternal trafficking of stem cells through the placenta. The amazing process known as fetal microchimerism allows a fetus to contribute stem cells to the mother which are capable of regenerating her damaged heart cells, and possibly a wide range of other cell types.

Curcuminandresveratrolhave been shown to improve recovery from spinal cord injury. Over a dozen other natural compounds hold promise in this area, which can be viewed on GreenMedinfosspinal cord injurypage online. As far as degenerative joint disease, i.e. osteoarthritis, there are a broad range of potentially regenerative substances, with 50 listed on the sitesosteoarthritisresearch page.

Regenerative medicine poses a unique challenge to the current medical paradigm, which is based on costly drug trials, patents, and an economic infrastructure supported by drug-based interventions. It is a simple truth that symptom suppression is profitable. It guarantees both the perpetuation of the original underlying disease and the generation of an ever-expanding array of additional, treatment-induced symptoms known as side effects.

But cures, especially those that come from natural sources, dont have this built-in income potential. Worse perhaps, from a Big Pharma perspective, they can not be easily patented. In the current regulatory environment, that means that companies have no incentive to conduct the costly trials required to have these cures approved by the FDA and then used in clinical settings. Without patents, they cant be controlled and sold.

But suppressing symptoms with drugs that cause side effects requiring other drugs is a non-sustainable, infinite growth model. It is doomed to fail and eventually collapse.

The current approach also interferes with the bodys natural regenerative and immune capabilities. Cultivating diets, lifestyles and attitudes conducive to bodily regeneration can interrupt this pathological circuit. With true health, we can attain the bodily freedom that is a precondition for the liberation of the human spirit.

SayerJiis the founder ofGreenmedinfo.com, a reviewer at theInternational Journal of Human Nutrition and Functional Medicine, co-founder and CEO ofSystome Biomed, vice chairman of the board of theNational Health Federation, and steering committee member of theGlobal GMO Free Coalition.This article was originally published on GreenMedinfo.com

See the original post:
6 Bodily Tissues That Can Be Regenerated Through Nutrition - The Epoch Times

The Future of Medicine is Here!

To help you return to the activities you love, our expert team at Triad Regenerative Medicine now offer Regenerative Cell Therapy procedures to help alleviate your pains without relying on complex surgical procedures or medication.

Of all bodily ailments, nothing is more painful and crippling than the persistent knee, hip or shoulder pain. Unfortunately, any damage to the ligaments, cartilage or bone by way of injury or disease (such as osteoarthritis), can cause severe pain and difficulty walking or partaking in your favorite activities. To help you return to the activities that you love, our expert team at Triad Regenerative Medicine now offer Regenerative Cell Therapy, based on a 21st-century therapeutic procedure to help alleviate your shoulder, hip, and knee pains without relying on complex surgical procedures or medication.

Regenerative Cell Therapy is one of the most effective treatments today that help the body to heal and regenerate tendon injuries, ligament damage, degenerative joint disease DJD and osteoarthritis. This procedure is non-invasive and harnesses your bodys natural healing potential to combat shoulder, hip and knee problems by the newly introduced cells stimulating existing healthy cells and tissues to operate at a higher level of function boosting the bodys repair mechanisms to aid in the healing process. The whole procedure takes approximately 30 minutes and has no known adverse side effects.

Regenerative Cell Therapy is one of the safest and most advanced approaches to treating a wide variety of injuries and diseases within the human body.

Patients recovering from injuries will rapidly improve exhibiting a greater mobility and less pain, compared to the lengthy and exhaustive period of post-surgical healing and rehabilitation.

Regenerative Cellular Medicine has opened the doors to medical advancements. We have only just begun to explore the amazing benefits. Praised notes of success thus far include the reduction or elimination of pain, increased strength and mobility, and quicker healing and recovery.

Originally posted here:
Triad Regenerative Medicine - Greensboro, NC